Skip to main
ANRO
ANRO logo

ANRO Stock Forecast & Price Target

ANRO Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Alto Neuroscience Inc. is advancing its clinical-stage pipeline with a strong focus on targeting depressive disorders and schizophrenia using brain-based biomarkers, which positions the company to potentially redefine treatment options in psychiatry. The recent updates highlight a resolute commitment to mitigating biases in its clinical designs, particularly in the ALTO-100 Phase 2b study, which, if successful, could enhance the overall efficacy and safety profile of its treatments. Additionally, the increasing valuation discount rate suggests a cautious yet optimistic outlook on the future performance of the company's stock amidst evolving clinical outcomes and strategic positioning.

Bears say

Alto Neuroscience Inc. experienced a significant setback with the ALTO-100 trial in major depressive disorder (MDD), leading to diminished confidence in its future MDD programs despite extensive efforts to ensure successful study execution. The disappointing results from the Phase 2b study, especially in a population targeted by cognitive biomarkers, raise concerns about the effectiveness of the company's treatment strategies and overall prospects for innovation in the sector. Additionally, there are potential risks associated with access to capital markets, which, if limited, could further adversely affect the company's financial stability and stock performance.

ANRO has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alto Neuroscience Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alto Neuroscience Inc (ANRO) Forecast

Analysts have given ANRO a Strong Buy based on their latest research and market trends.

According to 1 analysts, ANRO has a Strong Buy consensus rating as of Jul 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alto Neuroscience Inc (ANRO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.